42 research outputs found
One-pot radioiodination of aryl amines via stable diazonium salts: preparation of 125I-imaging agents
An operationally simple, one-pot, two-step tandem procedure that allows the incorporation of radioactive iodine into aryl amines via stable diazonium salts is described. The mild conditions are tolerant of various functional groups and substitution patterns, allowing late-stage, rapid access to a wide range of 125I-labelled aryl compounds and SPECT radiotracers
Rapid iododeboronation with and without gold catalysis: application to radiolabelling of arenes
Radiopharmaceuticals incorporating radioactive iodine in combination with SPECT imaging play a key role in nuclear medicine, with applications in drug development and disease diagnosis. Despite this importance, there are relatively few general methods for incorporating radioiodine into small molecules. Here we describe a rapid, air- and moisture-stable ipso-iododeboronation procedure using NIS, in the non-toxic and green solvent dimethyl carbonate. The fast reaction and mild conditions of the gold-catalysed method led to the development of a highly efficient process for radiolabelling of arenes, which constitutes the first example of an application of homogenous gold catalysis to selective radiosynthesis. This has been exemplified with an effective synthesis of radiolabelled meta-[125I]iodobenzylguanidine, a radiopharmaceutical used for the imaging and therapy of human norepinephrine transporter-expressing tumours
Late stage iodination of biologically active agents using a one-pot process from aryl amines
A simple and effective one-pot tandem procedure that generates aryl iodides from readily available aryl amines via stable diazonium salts has been developed. The operationally simple procedure and mild conditions allow late-stage iodination of a wide range of aryl compounds bearing various functional groups and substitution patterns. A novel synthetic strategy involving the preparation of nitroaryl compounds followed by a chemoselective tin(II) dichloride reduction and the use of the one-pot diazotisation–iodination transformation was also developed. The general applicability of this approach was demonstrated with the preparation of a number of medicinally important compounds including CNS1261, a SPECT imaging agent of the N-methyl-D-aspartate (NMDA) receptor and IBOX, a compound used to detect amyloid plaques in the brain
Exploring the functionalisation of the thieno[2,3-d]pyrimidinedione core: late stage access to highly substituted 5-carboxamide-6-aryl scaffolds
The thieno[2,3-d]pyrimidinedione core is found as a component in a range of pharmaceutically active
compounds, however, synthetic approaches to these scaffolds rely on access to functionalised, highly
substituted thiophenes. Here we describe a new approach for the preparation of 5-carboxamide-6-aryl
analogues that involves a two-step synthesis of the thieno[2,3-d]pyrimidinedione core from a readily
available mercaptouracil derivative. Thio-alkylation with ethyl 3-bromopyruvate, followed by cyclisation
and dehydration mediated by polyphosphoric acid allowed the scalable synthesis of the thieno[2,3-d]
pyrimidinedione unit. The late-stage functionalisation of this core motif via bromination of the thiophene
ring and a subsequent Suzuki-Miyaura reaction as the key steps permitted access to a novel library
of 5-carboxamide-6-aryl analogues. The physicochemical properties of these compounds were determined,
generating an insight into the potential bioavailability of these scaffolds. Based on these results, a
selection of the novel 5-carboxamide-6-aryl analogues were tested as lactate uptake inhibitors of
monocarboxylate transporters 1, 2 and 4 in Xenopus oocytes
Positron detection in silica monoliths for miniaturised quality control of PET radiotracers
We demonstrate the use of the miniaturised Medipix positron sensor for detection of the clinical PET radiotracer, [⁶⁸Ga]gallium-citrate, on a silica-based monolith, towards microfluidic quality control. The system achieved a far superior signal-to-noise ratio compared to conventional sodium iodide-based radio-HPLC detection and allowed real-time visualisation of positrons in the monolith
Inhibition of Poly(ADP-Ribose) polymerase enhances the toxicity of 131I-Metaiodobenzylguanidine/Topotecan combination therapy to cells and xenografts that express the noradrenaline transporter
Targeted radiotherapy using [131I]meta-iodobenzylguanidine ([131I]MIBG) has produced remissions in some neuroblastoma patients. We previously reported that combining [131I]MIBG with the topoisomerase I (Topo-I) inhibitor topotecan induced long-term DNA damage and supra-additive toxicity to NAT-expressing cells and xenografts. This combination treatment is undergoing clinical evaluation. This present study investigated the potential of PARP-1 inhibition, in vitro and in vivo, to further enhance [131I]MIBG/topotecan efficacy
Ligand-enabled copper-mediated radioiodination of arenes
The discovery of a copper precatalyst that facilitates the key mechanistic steps of arene halodeboronation has allowed a step change in the synthesis of radioiodine-containing arenes. The active precatalyst [Cu(OAc)(phen)2]OAc was shown to perform room temperature radio-iododeboronation of aryl boronic acids with 1–2 mol % loadings and 10 min reaction times. These mild conditions enable particularly clean reactions, as demonstrated with the efficient preparation of the radiopharmaceutical and SPECT tracer, meta-iodobenzylguanidine (MIBG).Peer reviewe
A novel 18F-labelled high affinity agent for PET imaging of the translocator protein
The translocator protein (TSPO) is an important target for imaging focal neuroinflammation in diseases such as brain cancer, stroke and neurodegeneration, but current tracers for non-invasive imaging of TSPO have important limitations. We present the synthesis and evaluation of a novel 3-fluoromethylquinoline-2-carboxamide, AB5186, which was prepared in eight steps using a one-pot two component indium(III)-catalysed reaction for the rapid and efficient assembly of the 4-phenylquinoline core. Biological assessment and the implementation of a physicochemical study showed AB5186 to have low nanomolar affinity for TSPO, as well as optimal plasma protein binding and membrane permeability properties. Generation of [18F]-AB5186 through 18F incorporation was achieved in good radiochemical yield and subsequent in vitro and ex vivo autoradiography revealed the ability of this compound to bind with specificity to TSPO in mouse glioblastoma xenografts. Initial positron emission tomography imaging of a glioma bearing mouse and a healthy baboon support the potential for [18F]-AB5186 use as a radiotracer for non-invasive TSPO imaging in vivo
Synthesis and evaluation of a radioiodinated tracer with specificity for poly(ADP-ribose) polymerase-1 (PARP-1) in vivo
Interest in nuclear imaging of poly(ADP-ribose) polymerase-1 (PARP-1) has grown in recent years due to the ability of PARP-1 to act as a biomarker for glioblastoma and increased clinical use of PARP-1 inhibitors. This study reports the identification of a lead iodinated analog 5 of the clinical PARP-1 inhibitor olaparib as a potential single-photon emission computed tomography (SPECT) imaging agent. Compound 5 was shown to be a potent PARP-1 inhibitor in cell-free and cellular assays, and it exhibited mouse plasma stability but approximately 3-fold greater intrinsic clearance when compared to olaparib. An (123)I-labeled version of 5 was generated using solid state halogen exchange methodology. Ex vivo biodistribution studies of [(123)I]-5 in mice bearing subcutaneous glioblastoma xenografts revealed that the tracer had the ability to be retained in tumour tissue and bind to PARP-1 with specificity. These findings support further investigations of [(123)I]-5 as a non-invasive PARP-1 SPECT imaging agent
An 18F-labeled poly(ADP-ribose) polymerase positron emission tomography imaging agent
Poly(ADP-ribose) polymerase (PARP) is involved in repair of DNA breaks
and is over-expressed in a wide variety of tumors, making PARP an attractive biomarker for
positron emission tomography (PET) and single photon emission computed tomography
imaging. Consequently, over the past decade, there has been a drive to develop nuclear
imaging agents targeting PARP. Here, we report the discovery of a PET tracer that is based
on the potent PARP inhibitor olaparib (1). Our lead PET tracer candidate, [18F]20, was
synthesized and evaluated as a potential PARP PET radiotracer in mice bearing
subcutaneous glioblastoma xenografts using ex vivo biodistribution and PET−magnetic
resonance imaging techniques. Results showed that [18F]20 could be produced in a good
radioactivity yield and exhibited specific PARP binding allowing visualization of tumors overexpressing
PARP. [18F]20 is therefore a potential candidate radiotracer for in vivo PARP
PET imaging